The Rotation Is Real
For two years, the GLP-1 narrative consumed nearly every conversation in healthcare investing. But as Eli Lilly and Novo Nordisk consolidate their commercial dominance, institutional capital is quietly rotating into the next wave – and mid-cap biotech is absorbing meaningful inflows for the first time since early 2021.
The XBI, the equal-weighted biotech ETF, is up 18.3% year-to-date through May 30, 2026 – outperforming the S&P 500 by approximately 6 percentage points. That divergence reflects genuine pipeline optionality, not speculative excess.
Where the Conviction Is Building
- Oncology: Next-generation ADC (antibody-drug conjugate) platforms from companies like Immunomedics successors and emerging players are showing durable response rates in Phase 2 data that exceed checkpoint inhibitor benchmarks
- Rare disease: Gene therapy approvals are accelerating – the FDA cleared three rare disease biologics in Q1 2026 alone, the highest quarterly rate on record
- Radiopharmaceuticals: Following Eli Lilly’s $2.4B acquisition of Point Biopharma in 2023, the space has attracted sustained deal flow and is now generating commercial revenue across multiple platforms
- Cardiometabolic beyond GLP-1: Oral small molecules targeting NASH, heart failure biomarkers, and renal protection are in late-stage trials with readouts expected H2 2026
The Valuation Case
The median enterprise value-to-pipeline asset ratio for mid-cap biotech currently sits at roughly 0.6x risk-adjusted NPV – a meaningful discount to the 0.9x to 1.1x range that historically precedes acquisition waves. Strategic acquirers including Pfizer, AstraZeneca, and Johnson & Johnson have all publicly signaled active business development mandates for 2026.
That M&A premium is not yet fully priced into the sector. It represents the asymmetric opportunity that makes biotech rotation worth sizing carefully into portfolios that can tolerate binary clinical risk.
Key Catalysts to Monitor
- ASCO 2026 data presentations (ongoing through early June) – oncology readouts move individual names 20 to 40% on single-day announcements
- FDA PDUFA dates for radiopharmaceutical and rare disease applications in Q3
- Any acceleration in large-cap deal announcements, which typically catalyze sector-wide re-rating
For informational purposes only.
About the Author
